论文部分内容阅读
近年来,急性白血病的联合化疗有了很大的进步,然急性单核细胞白血病(以下简称急单)病程凶险,死亡率甚高,目前尚无理想的药物,故急需寻找有效药物,探索新的治疗方案.ICRF159系双内酰亚胺的衍化物,是近年来治疗急性白血病有效药物之一,它能使病情缓解,延长寿命。我组自1973年9月初开始应用ICRF159治疗急单16例,兹报导于下:
In recent years, the great progress has been made in the combination chemotherapy of acute leukemia. However, there is no ideal medicine for acute monocytic leukemia (hereinafter referred to as acute single-cell) due to its extremely dangerous course and high mortality rate. Therefore, it is urgent to find effective drugs and explore new Of the treatment program.ICRF159 Department of double imide derivatives, is one of the effective drugs in the treatment of acute leukemia in recent years, it can ease the condition, prolong life. My group since the beginning of September 1973 application of ICRF159 treatment of urgent orders 16 cases, it is reported in the following: